JANX JANUX THERAPEUTICS INC Product Launches 8-K Filing 2024 - Clinical Data Update Janux Therapeutics announced promising interim clinical data for its JANX007 program, showing high response rates in prostate cancer patients, with 100% achieving PSA50 declines and 63% achieving PSA90 declines as of November 15, 2024.Get access to all SEC 8-K filings of the JANUX THERAPEUTICS INC